What are the NCCN and ESMO treatment guidelines for relapsed or refractory osteosarcoma?

Updated: Jul 01, 2020
  • Author: Charles T Mehlman, DO, MPH; Chief Editor: Omohodion (Odion) Binitie, MD  more...
  • Print

For relapsed or refractory osteosarcoma, NCCN guidelines recommend second-line chemotherapy, resection, or both. Options for disease progression after second-line therapy include the following [30] :

  • Re-resection, if possible
  • Clinical trial
  • Palliative radiation therapy or best supportive treatment

ESMO-PaedCan-EURACAN guidelines advise that the treatment of recurrent osteosarcoma is primarily surgical, in the case of isolated lung metastases, although stereotactic radiationa therapy, radiofrequency ablation, or cryotherapy might be alternative options in patients unfit for surgery. ESMO-PaedCan-EURACAN guidelines note that there is no accepted standard regimen for second-line chemotherapy for recurrent disease, but ifosfamide with or without etoposide with or without carboplatin, or gemcitabine and docetaxel or sorafenib may be considered. Radiation therapy, including samarium, may be used for palliation. [31]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!